FORM OF ORIGINAL ISSUE DISCOUNT CONVERTIBLE DEBENTURE DUE ON THE MATURITY DATERapid Therapeutic Science Laboratories, Inc. • May 31st, 2022 • Pharmaceutical preparations • New York
THIS ORIGINAL ISSUE DISCOUNT CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued Original Issue Discount Convertible Debentures of Rapid Therapeutic Science Laboratories, Inc., a Nevada corporation (the “Company”), having its principal place of business at 15800 Dooley Road, Suite 200, Addison, TX 75001, designated as its Original Issue Discount Convertible Debenture due on the Maturity Date (this debenture, the “Debenture” and, collectively with the other debentures of such series, the “Debentures”).
FORM OF COMMON STOCK PURCHASE WARRANT RAPID THERAPEUTIC SCIENCE LABORATORIES, INC.Rapid Therapeutic Science Laboratories, Inc. • May 31st, 2022 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on August 3, 2028 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Rapid Therapeutic Science Laboratories, Inc., a Nevada corporation (the “Company”), up to 388,236 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
FORM OF AMENDMENT, WAIVER AND PURCHASE AGREEMENTWaiver and Purchase Agreement • May 31st, 2022 • Rapid Therapeutic Science Laboratories, Inc. • Pharmaceutical preparations • New York
This Amendment, Waiver and Purchase Agreement (this “Agreement”) is made and entered into as of May 31, 2022 (the “Effective Date”) by and between Rapid Therapeutic Science Laboratories, Inc. (the “Company”) and ________________ (the “Purchaser” and together with the Company, the “Parties”) for the purpose of, among other things, (i) amending that certain Original Issue Discount Convertible Debenture due May 1, 2022 (the “Original Debenture”), (ii) amending that certain Common Stock Purchase Warrant to purchase 194,118 shares of Common Stock (after giving effect to the 1-for-25 reverse split on March 31, 2022) issued to the Purchaser (the “Original Warrant”), (iii) waiving any and all prior and currently existing events of default under the Original Debenture as of the date hereof, and (iv) agreeing to the purchase and sale of a new Original Issue Discount Convertible Debenture (in the form attached as Exhibit A hereto, the “New Debenture”) and common stock purchase warrant to purchase
